system: You are a contract-analysis assistant performing a span-extraction task. You are given an excerpt from a commercial contract and the name of a clause type to locate within it.

Return the exact text of the requested clause, copied verbatim from the excerpt — identical wording and punctuation, with no paraphrasing, summarising, explanation, or added commentary.

The excerpt is one window of a much longer contract and often will not contain the requested clause. If the requested clause does not appear in this excerpt, respond with exactly: Not found.

Output only the extracted clause text, or the exact string `Not found.` — nothing else.

user: Contract excerpt:
"""
division, continuation (in whole or in part) or request for continued examination of any of such patent, certificate of invention and patent application, and any patent or certificate of invention issuing thereon, and any reissue, reexamination, extension, restoration by any existing or future extension or restoration mechanism, division, renewal, substitution, confirmation, registration, revalidation, revision and addition of or to any of the foregoing. 1.49 "Person" means any individual, corporation, partnership, limited liability company, trust or other entity. 1.50 "Pharmacovigilance Agreement" has the meaning set forth in Section 4.5. 6 US-DOCS\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 1.51 "PMDA" means the Japanese Pharmaceuticals and Medical Devices Agency, and local counterparts thereto, and any successor agency(ies) or authority thereto having substantially the same function. 1.52 "Product" means Zogenix's proprietary fenfluramine product, known as Fintepla®, or any drug product containing a salt, enantiomer, or polymorph of fenfluramine. 1.53 "Product Invention" has the meaning set forth in Section 9.1(b)(i). 1.54 "Product Trademark" has the meaning set forth in Section 9.8(a). 1.55 "Public Official or Entity" means (a) any officer, employee (including physicians, hospital administrators or other healthcare professionals), agent, representative, department, agency, de facto official, representative, corporate entity, instrumentality or subdivision of any government, military or international organization, including any ministry or department of health or any state-owned or affiliated company or hospital, or (b) any candidate for political office, any political party or any official of a political party. 1.56 "Transfer Price" has the meaning set forth in Section 6.5(a). 1.57 "Receiving Party" has the meaning set forth in Section 8.1. 1.58 "Regulatory Approval" means any and all approvals (except NHI Price Listing), licenses, registrations, or authorizations of Regulatory Authorities in the applicable regulatory jurisdiction that are necessary for the manufacture, use, storage, import, transport and/or sale of a pharmaceutical product in such regulatory jurisdiction. 1.59 "Regulatory Authority" means any national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity whose review and/or approval is necessary for the manufacture, packaging, use, storage, import, export, distribution or promotion of a pharmaceutical product in the applicable regulatory jurisdiction, including the PMDA in the Territory. If governmental approval is required for pricing or reimbursement by national health insurance (or its local equivalent), "Regulatory Authority" shall also include any national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity whose review and/or approval of pricing or reimbursement is required. 1.60 "Regulatory Filings" means all applications, approvals, licenses, notifications, registrations, submissions and authorizations made to or received from a Regulatory Authority in connection with the development, manufacture or commercialization of a pharmaceutical product, including any INDs, MAAs and Regulatory Approvals. 1.61 "Regulatory Plan" has the meaning set forth in Section 4.2(a). 1.62 "SEC" means the U.S. Securities and Exchange Commission or any successor agency. 7 US-DOCS\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 1.63 "Sub-distributor" means any Person other than Distributor or its Affiliates that Distributor appoints to market, promote, offer for sale, sell, import or distribute the Product in the Field in the Territory, beyond the mere right to purchase the Product from Distributor or its Affiliates for end use. 1.64 "Supply Agreement" has the meaning set forth in Section 5.2. 1.65 "Territory" means Japan. 1.66 "Third Party" means any governmental authority or Person other than Zogenix, Distributor and their respective Affiliates. 1.67 "Third Party Claims" has the meaning set forth in Section 11.1. 1.68 "Trademark" means any word, name, symbol, color, designation or device or any combination thereof, including any trademark, trade dress, brand mark, service mark, trade name, brand name, logo or business symbol, whether or not registered, as determined in accordance with the trademark laws of the Unites States of America. 1.69 "United States" or "U.S." means the United States of America, including its territories and possessions and the District of Columbia. 1.70 "Unlabeled Drug Product" means [***]. 1.71 "Zogenix ex-Territory Distributor" means a licensee, collaborator or distributor engaged by Zogenix or any of its Affiliates to market, promote or sell the Product outside the Territory. 1.72 "Zogenix Indemnitees" has the meaning set forth in Section 11.1. 1.73 "Zogenix Know-How" means all Information and Data that Zogenix Controls as of the Effective Date or during the Term, which Information is necessary or reasonably useful to file for, obtain or maintain Regulatory Approval or to market, promote, sell, offer for sale or import the Product in the Field in the Territory. 1.74 "Zogenix Patents" means all Patents that Zogenix Controls as of the Effective Date or during the
"""

Extract the exact clause related to "Third Party Beneficiary" from the excerpt above.

assistant: Not found.